Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities: 2012-2024

Historic Total Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 5 years, with Dec 2024 value amounting to $121.4 million.

  • Agios Pharmaceuticals' Total Non-Current Liabilities fell 38.23% to $101.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.3 million, marking a year-over-year decrease of 38.23%. This contributed to the annual value of $121.4 million for FY2024, which is 2.87% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $121.4 million for FY2024, which was down 2.87% from $124.9 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Total Non-Current Liabilities peaked at $134.6 million during FY2022, and registered a low of $121.4 million during FY2024.
  • In the last 3 years, Agios Pharmaceuticals' Total Non-Current Liabilities had a median value of $124.9 million in 2023 and averaged $127.0 million.
  • Data for Agios Pharmaceuticals' Total Non-Current Liabilities shows a maximum YoY declined of 7.19% (in 2023) over the last 5 years.
  • Agios Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $134.6 million in 2022, then decreased by 7.19% to $124.9 million in 2023, then dropped by 2.87% to $121.4 million in 2024.